Current clinical, laboratory, and treatment outcome characteristics of visceral leishmaniasis: results from a seven-year retrospective study in Greece. (May 2015)

• Record Type: Journal Article
• Authors: Georgiadou, Sarah P.; Stefos, Aggelos; Spanakos, Gregory; Skrimpas, Stergios; Makaritsis, Konstantinos; Sipsas, Nikolaos V.; Dalekos, George N.
• Is Part Of: International journal of infectious diseases. Volume 34(2015:May)
• Page Start: 46
• Page End: 50
• Publication Date: 2015-05
• Subjects: Visceral leishmaniasis -- Parasite -- Liposomal amphotericin -- Haemophagocytic syndrome -- PCR; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2015.02.021
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: The diagnosis of visceral leishmaniasis (VL) is challenging as it is characterized by many atypical manifestations. Molecular methods contribute significantly to a prompt and timely diagnosis of VL. Early recognition of the clinical and laboratory characteristics of VL appears essential. The overall treatment efficacy with liposomal amphotericin (L-AMB) is very high. Summary: Objectives: Visceral leishmaniasis (VL) is re-emerging in endemic areas. The epidemiological, clinical, laboratory, and treatment outcome characteristics in a large cohort of VL patients is described herein. Methods: The cases of 67 VL patients (57% male, mean age 56 years) treated in two Greek hospitals over the last 7 years were identified and evaluated retrospectively. Results: Forty-six percent of patients reported contact with animals. Seventeen patients (25%) were immunocompromised, and 22% were co-infected with another pathogen. Sixty-four percent of patients had fever, 57% had weakness, 37% had sweats, 21% had weight loss, and 13% had a dry cough, while 6% developed haemophagocytic syndrome. The median duration of symptoms was 28 days. Fifty-eight percent of patients had splenomegaly, 49% had hepatomegaly, and 36% had lymphadenopathy. The diagnosis was established by positive PCR in peripheral blood (73%) and/or bone marrow specimens (34%). Sixty-one patients (91%) received liposomal amphotericin (L-AMB). Six patients (10%) did not respond or relapsed but were eventually cured after a second cycle of L-AMB. During a 6-month follow-up, the overall mortality was 9%, although none of these deaths was attributed to VL. Conclusions: VL is still a common disease in endemic areas, affecting immunocompetent and immunocompromised patients. Its diagnosis is challenging, and molecular techniques are valuable and helpful tools to achieve this. Treatment with L-AMB is safe and very effective.